| 
 |
Sign up online for a virtual consultation with Dr. Lamm, a pioneer in the treatment of bladder and other genitourinary cancers.
|
Printer Friendly
 |
|
|
Dr. Lamm's specially formulated and
tested multivitamin tablets deliver a
megadose of antioxidants that is
beneficial when combined with BCG
or other cancer treatment options.
|
|
| |
Abstract: Treatment of Renal Cell Carcinoma with 5-fluorouracil and Alfa-interferon
- REF: Urology. 1997 Dec;50(6):863-7; discussion 867-8. Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon. Gebrosky NP, Koukol S, Nseyo UO, Carpenter C, Lamm DL. Westmoreland Regional Hospital, Greensburg, Pennsylvania, USA.
Objectives
Renal cell carcinoma is relatively resistant to both chemotherapy and immunotherapy. Response, survival, duration of response, and toxicity of treatment were evaluated in patients with advanced renal cell carcinoma receiving a continuous intravenous infusion of 5-fluorouracil (5-FU) and low dose subcutaneous alfa-2b-interferon. Methods
Between 1989 and 1994, 21 patients with advanced renal cell carcinoma underwent treatment with continuous intravenous infusion of 5-FU, 200 mg/m2/day, and subcutaneous injections of recombinant interferon alfa-2b (IFN-alpha), 1 x 10(6) U/day.
Results
Objective response was observed in 9 patients (43%). Complete response occurred in 4 patients (19%): 2 with lung, 1 with bone, and 1 with liver metastasis. Partial response occurred in 5 patients (24%). Three of 4 complete responders remain alive without recurrence. Mean survival rate was 195 weeks among complete responders, 184 weeks among partial responders, and 88 weeks among nonresponders. The overall mean duration of response was 101 weeks. Responders developed progression of disease a mean of 62 weeks after the initial response to therapy. Mild dose-dependent toxicity was related to 5-FU infusion.
Nearly all toxicities subsided with the temporary cessation of 5-FU infusion and/or decreasing the dose of the infusion. Few if any of the toxicities appear to be directly related to the low dose interferon injections.
Conclusions
Although this study is based on a small sample size, we believe that the encouraging complete and partial responses, apparent prolongation of survival, and manageable toxicity of this combination therapy warrant further investigation with larger randomized trials.
| |
Home | Meet Dr. Lamm | About Us | Common Questions | Office Visit | e-Consultation
Cancer Information | Symptoms | Treatment & Prevention | Research | Forms | For Physicians
BCG Oncology, PC | 16620 North 40th Street, Suite E | Phoenix, AZ 85032 | (602) 493-6626
Copyright © 2007 BCG Oncology, PC. All rights reserved. Medical content authored by Donald L. Lamm, M.D., unless otherwise noted.
|
The information available on and through the BCGOncology.com Web site is presented in summary form as a supplement to, and NOT a substitute for, the knowledge, skill, and judgment of qualified physicians and health care professionals. The information on BCGOncology.com has been obtained from sources believed to be accurate and reliable. However, BCG Oncology, PC makes no warranty as to the accuracy, reliability, or completeness of this information. Information accessed on or through BCGOncology.com is neither complete nor exhaustive and does not cover all disabilities, diseases, illnesses, and physical conditions or their management or treatment. Information accessed on and through BCGOncology.com is provided "AS IS" and without warranty, express or implied, including, but not limited to, any implied warranty of merchantability or of fitness for a particular purpose. View our terms of use for more information. Donald L. Lamm, MD is licensed to practice medicine in the state of Arizona, only.
Site design and development by Alamo Web Pros, www.AlamoWebPros.com.
|
